The pipeline of antiviral T-cell therapy: what's in the clinic and undergoing development.
Clicks: 253
ID: 28457
2019
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Steady Performance
77.3
/100
249 views
202 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Virus-specific T cells allow targeting of multiple pathogens in patients after hematopoietic stem cell transplantation and have demonstrated potential efficacy for cytomegalovirus, Epstein-Barr Virus, and adenovirus. Novel targets may include BK virus, JC virus, varicella zoster virus, human herpesvirus 6, Aspergillus, human parainfluenza virus-3, herpes simplex virus Type I, Zika virus, and mycobacteria. Generation of patient-specific products and third-party products may expand feasibility of therapy.
| Reference Key |
fatic2019thetransfusion
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Fatic, Alyssa;Zhang, Nan;Keller, Michael D;Hanley, Patrick J; |
| Journal | transfusion |
| Year | 2019 |
| DOI |
10.1111/trf.15501
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.